Dr Iman Simmonds, MD, MPH | |
317 Foxon Rd Ste 2f, East Haven, CT 06513 | |
(475) 441-7809 | |
Not Available |
Full Name | Dr Iman Simmonds |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 317 Foxon Rd Ste 2f, East Haven, Connecticut |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104213297 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 301996 (New York) | Primary |
Entity Name | Docs Medical Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1104362169 PECOS PAC ID: 3173895000 Enrollment ID: O20170828000573 |
News Archive
Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
AlphaRx Inc. announced today that its licensee, Gaia BioPharma Limited, has signed an agreement with a contract manufacturing organization (CMO), to manufacture GAI-122 for use in the planned Phase I and II clinical trials of that product candidate. GAI-122 is being developed as I.V. administered formulation of an intracellular neuroprotectant that employs AlphaRx's proprietary nano-emulsion formulation technology.
Scientists make pivotal discovery of method for wireless modulation of neurons with X-rays that could improve the lives of patients with brain disorders. The X-ray source only requires a machine like that found in a dentist's office.
Marketing experts tackle health policy messaging, as the president campaigns for an ally and news organizations fact-check political claims.
SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Iman Simmonds, MD, MPH 317 Foxon Rd Ste 2f, East Haven, CT 06513-2038 Ph: (475) 441-7809 | Dr Iman Simmonds, MD, MPH 317 Foxon Rd Ste 2f, East Haven, CT 06513 Ph: (475) 441-7809 |
News Archive
Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
AlphaRx Inc. announced today that its licensee, Gaia BioPharma Limited, has signed an agreement with a contract manufacturing organization (CMO), to manufacture GAI-122 for use in the planned Phase I and II clinical trials of that product candidate. GAI-122 is being developed as I.V. administered formulation of an intracellular neuroprotectant that employs AlphaRx's proprietary nano-emulsion formulation technology.
Scientists make pivotal discovery of method for wireless modulation of neurons with X-rays that could improve the lives of patients with brain disorders. The X-ray source only requires a machine like that found in a dentist's office.
Marketing experts tackle health policy messaging, as the president campaigns for an ally and news organizations fact-check political claims.
SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.
› Verified 2 days ago